NeoGenomics Q2 FY26 adjusted EBITDA climbs 36% to $14 million; revenue rises 11% to $202 million
NEO•Q2 revenue and profitability improve
NeoGenomics posted Q2 2026 revenue of $202 million, up 11% year over year.
Adjusted EBITDA climbed 36% to $14 million, lifting adjusted EBITDA margin 130 basis points to 7.2%.
Operating expense fell 3% to $102 million; period-end cash totaled $146 million following $20 million of operating cash flow.
Volume growth and updated full-year outlook
NGS revenue rose 26% year over year on 14% higher volume; clinical volume increased 2% to 363,000 tests.
NeoGenomics raised full-year 2026 revenue guidance to $802 million-$806 million, projecting adjusted EBITDA of $56 million-$58 million.
